



March 18, 2024

Company name: SanBio Co., Ltd.  
Representative: Keita Mori, Representative  
Director and President  
(TSE Growth Code: 4592)  
Contact: Yoshihiro Kakutani,  
Corporate Officer of  
Management Administration  
(TEL. +81-3-6264-3481)

**Further Update on Status of Manufacturing and Marketing Approval for  
SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan**

SanBio Co., Ltd. hereby provides an update on this matter as per the attached document.



March 18, 2024  
SanBio Co., Ltd.

## **Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan**

On January 25, 2024, SanBio Co., Ltd. (the “Company”) provided an update on the progress toward obtaining marketing approval of SB623 to treat chronic traumatic brain injury (TBI) in Japan, stating it aims to achieve approval by March 2024 and is actively engaged in the review process.

Today, the Ministry of Health, Labour and Welfare announced that the Pharmaceutical Affairs and Food Sanitation Council’s Subcommittee on Regenerative Medicine Products (the “Subcommittee”) will hold a meeting on March 25, and we learned that SB623, our development regenerative medicine product “AKUUGO suspension for intracranial implantation,” is included in the agenda for the meeting. When the approval of a product is deliberated in the Subcommittee, the agenda usually includes the phrase “regarding the approval or disapproval of the manufacturing and marketing authorization.” However, this phrase is not included in the current agenda. Moreover, the outcome of the deliberations will not be known until after the Subcommittee meeting on March 25. Therefore, the Company requests your cautious handling of today’s announcement.

### **About SB623**

SB623 (INN: vandefitemcel) is a human (allogeneic) bone marrow-derived modified mesenchymal stem cell that is produced by modifying and culturing mesenchymal stem cells derived from the bone marrow aspirate of healthy adults. Implantation of SB623 cells into injured nerve tissues in the brain is expected to trigger the brain’s natural regenerative ability to restore lost functions. SB623 is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and ischemic stroke.

### **About Traumatic Brain Injury**

Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide. The estimated global incidence of acute TBI during 2016 was 27 million cases, and the estimated global prevalence of chronic impairment secondary to TBI was 55.5 million cases.<sup>1</sup> Overall, TBI and long-term motor deficits secondary to TBI significantly impair a person’s self-care, employability, and quality of life, and are major burdens on healthcare systems worldwide. In the United States, approximately 43% of surviving hospitalized persons with

TBI experience long-term disabilities,<sup>2</sup> and it is estimated that 3.17 million people are living with long-term disabilities secondary to TBI.<sup>3</sup>

**About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)**

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Company's propriety regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and stroke. The Company is headquartered in Tokyo, Japan and Oakland, California, and additional information about SanBio Group is available at <https://sanbio.com/en/>

<References>

1 James SL, et al. "Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990- 2016: a systematic analysis for the Global Burden of Disease Study 2016." *Lancet Neurol* 2019;18:56-87.

2 Selassie AW, et al. "Incidence of long-term disability following traumatic brain injury hospitalization, U.S.", 2003. *J Head Trauma Rehabil* 2008;23:123-31

3 Zaloshnja E, Miller T, Langlois JA, Selassie AW. "Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005." *J Head Trauma Rehabil.* 2008 Nov-Dec;23(6):394-400.

**For more information, contact:**

SanBio Co., Ltd.  
Management Administration  
Email: [info@sanbio.com](mailto:info@sanbio.com)